Abstract: The invention relates to the use of Alum for the preparation of a drug for enhancing an antigen-specific type 1 immune response against an antigen in the presence of a type 1 inducing adjuvant.
Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. epidermidis, methods for isolating such antigens and specific uses thereof.
Type:
Application
Filed:
March 31, 2004
Publication date:
February 15, 2007
Applicant:
InterCell AG
Inventors:
Andreas Meinke, Duc Min Bui, Eszter Nagy
Abstract: Disclosed is a Hepatitis C virus (HCV) vaccine comprising at least two epitopes, each from a different hotspot epitope, wherein a hotspot epitope is defined as an epitope containing peptide selected from the group consisting of KFPGGGQIVGGVYLLPRRGPRLGVRATRK, GYKVLVLNPSVAAT, AYAAQGYKVLVLNPSVAAT, DLMGYIP(A/L)VGAPL, GEVQVVSTATQSFLATCINGVCWTV, HMWNFISGIQYLAGLSTLPGNPA, VDYPYRLWHYPCT(V/I)N(F/Y)TIFK(V/I)RMYVGGVEHRL, AAWYELTPAETTVRLR, GQGWRLLAPITAYSQQTRGLLGCIV, IGLGKVLVDILAGYGAGVAGALVAFK, FTDNSSPPAVPQTFQV, LEDRDRSELSPLLLSTTEW, YLVAYQATVCARAQAPPPSWD, MSTNPKPQRKTKRNTNR, LINTNGSWHINRTALNCNDSL, TTILGIGTVLDQAET, FDS(S/V)VLCECYDAG(A/C)AWYE, ARLIVFPDLGVRVCEKMALY, AFCSAMYVGDLCGSV, GVLFGLAYFSMVGNW, VVCCSMSYTWTGALITPC, TRVPYFVRAQGLIRA and TTLLFNILGGWVAAQ.
Type:
Application
Filed:
July 9, 2004
Publication date:
February 8, 2007
Applicant:
Intercell AG
Inventors:
Michael Buschle, Jurgen Frisch, Christoph Klade, Karen Lingnau, Wolfgang Zauner, Gerd Zettlmeissl
Abstract: The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.
Type:
Grant
Filed:
June 7, 2001
Date of Patent:
December 12, 2006
Assignee:
Intercell AG
Inventors:
Alena Egyed, Karen Lingnau, Frank Mattner, Michael Buschle, Walter Schmidt
Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens and specific uses thereof.
Type:
Application
Filed:
May 6, 2004
Publication date:
November 30, 2006
Applicant:
Intercell AG
Inventors:
Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZXZN-XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
Type:
Application
Filed:
March 22, 2004
Publication date:
November 23, 2006
Applicant:
Intercell AG
Inventors:
Michael Buschle, Andre Habel, Jorg Fritz, Karin Prinz, Karen Lingnau
Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating such antigens and specific uses thereof.
Type:
Application
Filed:
April 15, 2004
Publication date:
November 23, 2006
Applicant:
InterCell AG
Inventors:
Andreas Meinke, Eszter Nagy, Markus Hanner, Shallesh Dewasthaly, Ulrike Stierschneider
Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from C. pneumoniae, methods for isolating such antigens and specific uses thereof.
Type:
Application
Filed:
June 16, 2004
Publication date:
October 26, 2006
Applicant:
Intercell AG
Inventors:
Andreas Meinke, Eszter Nagy, Birgit Winkler
Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.
Type:
Application
Filed:
August 27, 2003
Publication date:
September 28, 2006
Applicant:
Intercell AG
Inventors:
Michael Buschle, Andre Habel, Christoph Klade, Frank Mattner, Oleksandr Otava, Oresta Vytvytska, Wolfgang Zauner, Sandra Zinke, Helen Kirlappos
Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from H. pylori, methods for isolating such antigens and specific uses thereof.
Type:
Application
Filed:
April 22, 2004
Publication date:
August 31, 2006
Applicant:
Intercell AG
Inventors:
Andreas Meinke, Du Min Bui, Eszter Nagy, Tamas Henics
Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S.
Type:
Application
Filed:
March 2, 2004
Publication date:
August 31, 2006
Applicant:
InterCell AG
Inventors:
Andreas Meinke, Eszter Nagy, Birgit Winkler, Dieter Gelbmann
Abstract: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine.
Type:
Application
Filed:
October 15, 2003
Publication date:
June 1, 2006
Applicant:
InterCell AG
Inventors:
Dieter Reinscheid, Heike Gutekunst, Axel Schubert, Bernhard Eikmanns, Andreas Meinke
Abstract: The present invention provides the use of molecules, which interact with the haptoglobin receptor ligand binding for the preparation of a medicament to prevent and treat Staphylococcus infection.
Type:
Application
Filed:
June 18, 2003
Publication date:
October 6, 2005
Applicant:
Intercell AG
Inventors:
Eszter Nagy, Agnieszka Dryla, Dieter Gelbmann
Abstract: A vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants is present in the form of a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions. Preferably, it contains substances capable of making the vaccine isotonic, particularly sorbitol.
Type:
Grant
Filed:
January 27, 1999
Date of Patent:
March 22, 2005
Assignee:
Intercell AG
Inventors:
Michael Buschle, Max Birnstiel, Walter Schmidt